



## Company Profile

**Golden Meditech Holdings Limited** (“Golden Meditech” or the “Company,” together with its subsidiaries collectively as the “Group,” 0801.HK, 910801.TW) is a leading player in integrated medical device and healthcare services in China, thanks to our strengths in innovation and market expertise, and the ability in capturing emerging market opportunities.

Golden Meditech is recognized as a first-mover in China’s healthcare industry with a proven track-record in identifying, grooming and establishing dominant positions in specialist market segments within the industry, including blood-related medical devices, cord blood banking, and hospital management and related healthcare services.

## Investment Thesis

As a leading player in integrated healthcare services and medical devices in China, the Group has a strong presence in niche and lucrative markets, and seasoned management team with proven execution capabilities :

- ✦ First foreign-owned company with a nationwide hospitals management license and currently managing the two largest hematology specialist hospitals in China
- ✦ First and largest blood-related medical device manufacturer
- ✦ First medical insurance claim processing and settlement BPO service provider

## Growth Strategies

- ✦ Proven strategy and track record in identifying, grooming, penetrating and establishing dominant operators within emerging markets within the healthcare industry in China
- ✦ Focus on medical device and healthcare service operations , addressing both hospital and general public markets
- ✦ Invest in healthcare projects with huge market potential, limited competition and great investment returns
- ✦ Enhance shareholder value through the successful listing of operations

## Our Business Segments

### The Healthcare Services Segment

#### GM Hospital Management

Focusing on hospital management and related services, the Group is the first and only foreign company with a nationwide hospital management license in China. We are currently managing the two largest hematology specialist hospitals in China.

#### GM Medicare

The Group established GM Medicare in April 2010, a leading provider of medical insurance information management systems and back-office business process outsourcing services in China, assisting both foreign and domestic medical insurance companies in claim processing and settlement administration in China.

#### Cord Blood Banking Operations

The Group is the founding and substantial shareholder of China Cord Blood Corporation (NYSE:CO), the first and largest umbilical cord blood bank in China with exclusive licenses for Beijing, Guangdong, Zhejiang, and a stake in the operator in Shandong. CCBC is also the single largest shareholder of Cordlife Ltd. (CBB:AX), Southeast Asia’s largest cord blood bank operator.

### The Medical Device Segment

#### Beijing Jingjing Medical Equipment Co., Ltd.

Primarily engaged in the development, manufacture, sales and distribution of blood-related medical devices, the Group’s focus is on the development of technologies for blood recovery, purification, treatment and preservation during surgery.

Our key products includes the Autologous Blood Recovery System (the “ABRS”), the first of its kind to obtain the approval of State Food and Drug Administration (“SFDA”), the Plasma Exchange System and the Accelerated Thermostatic Infusion Pump.



## Medium Term Strategic Objectives

- Market penetration and new healthcare product or service developments as key drivers for segment growth
- Continue to identify promising new products know-how, technology to fuel the company long-term growth
- Leverage on the existing healthcare services and ride on PRC government policy to enhance market position

## Corporate Information

Stock Code	<b>0801.HK</b>
Date of Listing	28 December, 2001
Founder & Chairperson	Mr. KAM Yuen
Name of Directors	<b>Executive Directors:</b> Mr. KAM Yuen, Mr. LU Tian Long, Ms. JIN Lu, Ms. ZHENG Ting  <b>Independent Non-executive Directors:</b> Mr. GAO Zong Ze, Prof. CAO Gang, Prof. GU Qiao Prof. CAO Gang (Chairman), Mr. GAO Zong Ze, Prof. GU Qiao
Audit Committee	
Shareholders (as of June 30, 2011)	77.73% Public 22.27% Mr. KAM Yuen and family trusts  <i>Other persons who with over 5% interest</i> 22.66% Mr Kent C. MCCARTHY and Jayhawk China Fund (Cayman) Ltd 6.62% Top Strength Holdings Limited 3.24% Martin Currie (Holdings) Ltd.
Issued Shares	1,989,031,827 (on 30 March 2012)
Par Value of Ordinary Shares	HK\$0.10 each
Board lot size	4,000 shares
Financial Year End Date	March 31 <sup>st</sup>
Auditors	KPMG
Legal Adviser	Minter Ellison Lawyers
Beijing Office:	No.11, Wan Yuan Street, Beijing Economic-Technological Development Area, Beijing 100176 China
Hong Kong Office:	48/F, Bank of China Tower, 1 Garden Road, Central, Hong
Website	<a href="http://www.goldenmeditech.com">www.goldenmeditech.com</a>

For further inquiries, please contact: Investor Relations Department,  
**Golden Meditech Holdings Limited**  
48/F, Bank of China Tower, 1 Garden Road, Central, Hong Kong.  
Tel: +852 3605 8138  
Fax: +852 3605 8181  
Email: [ir@goldenmeditech.com](mailto:ir@goldenmeditech.com)  
Website: [www.goldenmeditech.com](http://www.goldenmeditech.com)